To further highlight the changes of TCRR distribution in RA patients treated with different DMARDs, 3 subgroups were set up from CC based on different regimens: 80 patients (50.64%) treated with MTX (methotrexate); 71 patients (45.51%) treated with MTX and glucocorticoid (GC) and 5 patients (3.85%) treated with etanercept (TNF inhibitor, TNFi). The gene discussed is TNF; the disease is rheumatoid arthritis.